Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus

Abstract

Aim: To molecularly characterize the tumor microenvironment and evaluate immunologic parameters in canine glioma patients before and after treatment with oncolytic human IL-12-expressing herpes simplex virus (M032) and in treatment naïve canine gliomas.

Methods: We assessed pet dogs with sporadically occurring gliomas enrolled in Stage 1 of a veterinary clinical trial that was designed to establish the safety of intratumoral oncoviral therapy with M032, a genetically modified oncolytic herpes simplex virus. Specimens from dogs in the trial and dogs not enrolled in the trial were evaluated with immunohistochemistry, NanoString, Luminex cytokine profiling, and multi-parameter flow cytometry.

Results: Treatment-naive canine glioma microenvironment had enrichment of Iba1 positive macrophages and minimal numbers of T and B cells, consistent with previous studies identifying these tumors as immunologically “cold”. NanoString mRNA profiling revealed enrichment for tumor intrinsic pathways consistent with suppression of tumor-specific immunity and support of tumor progression. Oncolytic viral treatment induced an intratumoral mRNA transcription signature of tumor-specific immune responses in 83% (5/6) of canine glioma patients. Changes included mRNA signatures corresponding with interferon signaling, lymphoid and myeloid cell activation, recruitment, and T and B cell immunity. Multiplexed protein analysis identified a subset of oligodendroglioma subjects with increased concentrations of IL-2, IL-7, IL-6, IL-10, IL-15, TNFα, GM-CSF between 14 and 28 days after treatment, with evidence of CD4⁺ T cell activation and modulation of IL-4 and IFNγ production in CD4⁺ and CD8⁺ T cells isolated from peripheral blood.

Conclusion: These findings indicate that M032 modulates the tumor-immune microenvironment in the canine glioma model.

Keywords

Oncolytic herpes virus / M032 / canine glioma / large animal model / tumor microenvironment / NanoString

References

[1] WellerM,AldapeK.Glioma.Nat Rev Dis Primers2015;1:15017

[2] WenPY.Malignant gliomas in adults.N Engl J Med2008;359:492-507

[3] SiegelRL,FuchsHE.Cancer statistics, 2021.CA Cancer J Clin2021;71:7-33

[4] OstromQT,CioffiG,KruchkoC.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017.Neuro Oncol2020;22:iv1-iv96 PMCID:PMC7596247

[5] ParkJS,ModianoJF.Canine cancer immunotherapy studies: linking mouse and human.J Immunother Cancer2016;4:97 PMCID:PMC5171656

[6] ChambersMR,CrossmanDK.The one health consortium: design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in combination with a checkpoint inhibitor in canine patients with sporadic high grade gliomas.Front Surg2020;7:59 PMCID:PMC7484881

[7] DeCordovaS,TsolakiAG.Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma.Front Immunol2020;11:1402 PMCID:PMC7379131

[8] KijimaN.Mouse models of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017. p. 131-9.

[9] LentingK,TerLaan M,LeendersW.Glioma: experimental models and reality.Acta Neuropathol2017;133:263-82 PMCID:PMC5250671

[10] MiyaiM,SoedaA,IwamaT.Current trends in mouse models of glioblastoma.J Neurooncol2017;135:423-32 PMCID:PMC5700231

[11] PerelP,SenaE.Comparison of treatment effects between animal experiments and clinical trials: systematic review.BMJ2007;334:197 PMCID:PMC1781970

[12] U.S. Department of Health and Human Services, FDA. Challenge and opportunity on the critical path to new medical technologies. March, 2004. Available from: https://www.who.int/intellectualproperty/documents/en/FDAproposals.pdf [Last accessed on 21 Oct 2021]

[13] AlvarezCE.Naturally occurring cancers in dogs: insights for translational genetics and medicine.ILAR J2014;55:16-45

[14] KoehlerJW,MillerCR.A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma.J Neuropathol Exp Neurol2018;77:1039-54 PMCID:PMC6181180

[15] RichardsKL,ChenHW.Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.Cancer Res2013;73:5029-39 PMCID:PMC3755352

[16] FengerJM,KisseberthWC.Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.ILAR J2014;55:69-85

[17] HicksJ,KentM.Canine brain tumours: a model for the human disease?.Vet Comp Oncol2017;15:252-72

[18] PriesterWA.The occurrence of tumors in domestic animals.Natl Cancer Inst Monogr1980;(54):1-210

[19] SnyderJM,WinkleTJ.Canine intracranial primary neoplasia: 173 cases (1986-2003).J Vet Intern Med2006;20:20-75

[20] MillerAD,RossmeislJH.Canine primary intracranial cancer: a clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors.Front Oncol2019;9:1151 PMCID:PMC6856054

[21] Estevez-OrdonezD,SalehaniA.Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas.Neurosurg Clin N Am2021;32:265-81

[22] ChouJ,WhitleyRJ.Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.Science1990;250:1262-6

[23] FriedmanGK,ChenD.Enhanced sensitivity of patient-derived pediatric high-grade brain tumor xenografts to oncolytic HSV-1 virotherapy correlates with nectin-1 expression.Sci Rep2018;8:13930 PMCID:PMC6141470

[24] NguyenHM,SahaD.Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy.Cells2020;9:400 PMCID:PMC7072539

[25] PavlinD,SersaG.IL-12 based gene therapy in veterinary medicine.J Transl Med2012;10:234 PMCID:PMC3543347

[26] OmarNB,CrossmanDK.Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.Neurosurg Focus2021;50:E5 PMCID:PMC8383155

[27] GoulartMR,ChangYM.Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells.Sci Rep2019;9:3574 PMCID:PMC6400936

[28] JacksonK,DotyA.Analysis of canine myeloid-derived suppressor cells (MDSCs) utilizing fluorescence-activated cell sorting, RNA protection mediums to yield quality RNA for single-cell RNA sequencing.Vet Immunol Immunopathol2021;231:110144

[29] MasonNJ,OverleyB.RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.Gene Ther2008;15:955-65

[30] MoreiraML,SoaresRP.Cross-reactivity of commercially available anti-human monoclonal antibodies with canine cytokines: establishment of a reliable panel to detect the functional profile of peripheral blood lymphocytes by intracytoplasmic staining.Acta Vet Scand2015;57:51 PMCID:PMC4566394

[31] RotheK,BüttnerM,vonButtlar H.Canine peripheral blood CD4⁺CD8⁺ double-positive Tcell subpopulations exhibit distinct Tcell phenotypes and effector functions.Vet Immunol Immunopathol2017;185:48-56

[32] DaltonMF,KrimerPM,RissiDR.Clinicopathologic features, diagnosis, and characterization of the immune cell population in canine choroid plexus tumors.Front Vet Sci2019;6:224 PMCID:PMC6646530

[33] RissiDR,BoudreauCE,MillerAD.Immunohistochemical characterization of immune cell infiltration in feline glioma.J Comp Pathol2018;160:15-22

[34] MasonN,PiazzaE.Abstract 1693: Multi-national, multi-center collaboration to develop a novel gene expression tool for comparative translational immuno-oncology.Cancer Res2021;81:1693

[35] FraserAR,leChevoir MA.Epidermal growth factor receptor and Ki-67 expression in canine gliomas.Vet Pathol2016;53:1131-7

[36] PiCastro D,FernándezFlores F.Expression of FOXP3 in canine gliomas: immunohistochemical study of tumor-infiltrating regulatory lymphocytes.J Neuropathol Exp Neurol2020;79:184-93

[37] ToedebuschR,DickinsonPJ.Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma.Neurooncol Adv2021;3:vdab062 PMCID:PMC8193901

[38] FilleyA,BhowmikT.Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas.J Neurooncol2018;137:469-79 PMCID:PMC5924594

[39] SlomaEA,ErbHN.Characterization of inflammatory changes associated with canine oligodendroglioma.J Comp Pathol2015;153:92-100

[40] TomaszewskiW,GajewskiTF.Brain tumor microenvironment and host state: implications for immunotherapy.Clin Cancer Res2019;25:4202-10 PMCID:PMC6635001

[41] BonaventuraP,AlcazerV.Cold tumors: a therapeutic challenge for immunotherapy.Front Immunol2019;10:168 PMCID:PMC6376112

[42] LouieRJ,JajjaMR.Real-world outcomes of talimogene laherparepvec therapy: a multi-institutional experience.J Am Coll Surg2019;228:644-9

[43] AndtbackaRHI,AmatrudaT.OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.JCO2013;31:LBA9008

[44] FrankeV,KlopWMC.High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).Int J Cancer2019;145:974-8

[45] RibasA,PuzanovI.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.Cell2017;170:1109-19.e10 PMCID:PMC8034392

[46] KaufmanHL,DeRaffeleG,CoffinRS.Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Ann Surg Oncol2010;17:718-30

[47] BenenciaF,Conejo-GarcíaJR.HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.Mol Ther2005;12:789-802

[48] ReinertLS,WintherH.Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defence in the CNS.Nat Commun2016;7:13348 PMCID:PMC5109551

[49] MaW,WangH.Oncolytic herpes simplex virus and immunotherapy.BMC Immunol2018;19:40 PMCID:PMC6299639

[50] KaufmanHL,ZlozaA.Oncolytic viruses: a new class of immunotherapy drugs.Nat Rev Drug Discov2015;14:642-62 PMCID:PMC7097180

[51] NayakL,PetersK.Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma.Clin Cancer Res2021;27:1048-57 PMCID:PMC8284901

[52] IorgulescuJB,SperanzaMC.Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma.Clin Cancer Res2021;27:276-87 PMCID:PMC8034990

[53] OtvosB,GrabowskiMM.Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome.Clin Cancer Res2021;27:2038-49 PMCID:PMC8026586

[54] ChongsathidkietP,KoyamaS.Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.Nat Med2018;24:1459-68 PMCID:PMC6129206

[55] FriedmanGK,BagAK.Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas.N Engl J Med2021;384:1613-22 PMCID:PMC8284840